Executives Sell Over $100M Of 4 Stocks

12:44pm, Wednesday, 01'st Jun 2022 Benzinga
Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or

Real Estate Trends for Investors to Watch

10:45pm, Tuesday, 31'st May 2022 The Motley Fool
We've got interviews with the CEOs of RE/MAX and Alexandria Real Estate Equities.
Shares of Eli Lilly & Co. LLY, -4.05% fell 4.0% in afternoon trading Tuesday, to pullback from the previous session's record close, after the drug maker disclosed that its largest shareholder sold nea

Executives Sell Around $96M Of 5 Stocks

12:28pm, Tuesday, 31'st May 2022 Benzinga
US stocks closed higher on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view th
Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.

3 Dividend Stocks You Can Buy and Hold Forever

11:31am, Sunday, 29'th May 2022 The Motley Fool
Their strong underlying businesses should keep the quarterly payouts flowing to shareholders.

3 Dividend Stocks You Can Buy and Hold Forever

07:31am, Sunday, 29'th May 2022
Their strong underlying businesses should keep the quarterly payouts flowing to shareholders.

Is This Dividend Growth Stock a Buy?

02:37pm, Friday, 27'th May 2022 The Motley Fool
Eli Lilly has especially crushed the S&P 500 index year to date.

3 Reasons to Buy and Hold This Dividend Stock

02:00pm, Friday, 27'th May 2022 The Motley Fool
Amgen's 3.1% dividend yield is nearly double the S&P 500's -- and that's not the only thing to like about the stock.

Is This Dividend Growth Stock a Buy?

10:37am, Friday, 27'th May 2022
Eli Lilly has especially crushed the S&P 500 index year to date.
Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT
Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.

Executives Sell Around $207M Of 5 Stocks

12:10pm, Wednesday, 25'th May 2022 Benzinga
Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or

Why This FDA Approval Is a Game Changer for Eli Lilly

02:53pm, Tuesday, 24'th May 2022 The Motley Fool
It could mean billions in revenue for the company.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE